Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target

Benzinga · 3d ago
Goldman Sachs analyst Andrea Newkirk reinstates AbCellera Biologics (NASDAQ:ABCL) with a Neutral and announces $13 price target.